MedMatrix Rx
Daily 340B Morning Briefing for Executives
Recent developments surrounding the 340B program have intensified as hospitals and drug manufacturers engage in legal battles over the revised rebate model. The American Hospital Association and other entities have filed a lawsuit to block the 340B rebate pilot, citing potential costs exceeding $1 billion. In response, drugmakers including AbbVie and Bristol Myers Squibb have sought to intervene in the lawsuit, defending their rebate plans approved by HRSA. Concurrently, bipartisan legislation has been introduced to delay the implementation of the rebate pilot for two years, mandating upfront discounts during this period. An HHS report has also raised concerns about the program’s growth and its implications for hospital profits and patient care.
EXECUTIVE SUMMARY
01
Hospitals sue to block 340B rebate pilot.
The American Hospital Association and others filed a lawsuit challenging HHS’s revised 340B rebate program, citing over $1 billion in potential costs.
The American Hospital Association and others filed a lawsuit challenging HHS’s revised 340B rebate program, citing over $1 billion in potential costs.
Source: Becker’s Hospital Review
02
Drugmakers seek to join 340B rebate lawsuit.
AbbVie, Bristol Myers Squibb, and PhRMA filed motions to intervene in the lawsuit against HRSA’s 340B rebate model, defending their approved plans.
AbbVie, Bristol Myers Squibb, and PhRMA filed motions to intervene in the lawsuit against HRSA’s 340B rebate model, defending their approved plans.
Source: Becker’s Hospital Review
03
Bill introduced to delay 340B rebate pilot.
Bipartisan legislation proposes delaying HRSA’s 340B rebate model pilot for two years, requiring upfront discounts during this period.
Bipartisan legislation proposes delaying HRSA’s 340B rebate model pilot for two years, requiring upfront discounts during this period.
Source: Becker’s Hospital Review
04
HRSA approves 340B rebate plans.
HRSA approved rebate plans from 10 drug manufacturers for its revised 340B Rebate Model Pilot Program, effective January 1, 2027.
HRSA approved rebate plans from 10 drug manufacturers for its revised 340B Rebate Model Pilot Program, effective January 1, 2027.
Source: MENAFN
05
HHS report flags 340B program concerns.
An HHS report raises concerns about the 340B program’s growth and its impact on hospital profits and patient care.
An HHS report raises concerns about the 340B program’s growth and its impact on hospital profits and patient care.
Source: TechTarget
06
Lilly faces lawsuits over 340B claims data policy.
Hospitals are challenging Eli Lilly’s 340B claims data requirements in federal court, with no rulings yet.
Hospitals are challenging Eli Lilly’s 340B claims data requirements in federal court, with no rulings yet.
Source: Becker’s Hospital Review
07
340B litigation updates.
Recent court filings include motions and responses in various 340B-related lawsuits across the country.
Recent court filings include motions and responses in various 340B-related lawsuits across the country.
Source: NewsBreak
EXECUTIVE SUMMARY — KEY TAKEAWAYS
Most important 340B implication. The ongoing litigation and legislative efforts surrounding the 340B program have significant implications for covered entities, particularly hospitals. As they assess the potential financial impacts of the revised rebate model, the uncertainty surrounding the program could affect their operational budgets and ability to provide care. The proposed delay in the rebate pilot may offer temporary relief, but the overarching concerns raised in the HHS report about the program’s sustainability and its effects on patient care remain critical. Covered entities must prepare for changes, balancing the need for financial viability with their commitment to serving vulnerable populations, which could ultimately influence their strategic planning and resource allocation.
Emerging risks.
- Hospitals face significant financial risks if the 340B rebate pilot proceeds, with potential administrative costs exceeding $1 billion annually.
- Drugmakers’ intervention in the lawsuit may delay legal proceedings and prolong uncertainty for hospitals.
- The HHS report notes potential risks of increased hospital consolidation and higher premiums due to the 340B program’s growth.
Emerging opportunities.
- The delay in the 340B rebate pilot provides Congress with an opportunity to consider comprehensive 340B reforms.
- Hospitals can use the compliance requirements of the revised 340B rebate pilot to improve audit readiness and program integrity.
- Drugmakers may find opportunities to collaborate with hospitals on alternative pricing models that balance transparency and financial viability.
- The CMS proposal to cut 340B payments opens discussions on aligning Medicare payments with hospital drug acquisition costs.
Key actions for providers.
- Hospitals should prepare for potential financial impacts by reviewing their 340B program strategies and budgeting for possible changes.
- Engage with policymakers to advocate for 340B reforms that support hospital financial stability and patient care.
- Monitor ongoing litigation closely to understand potential legal and financial implications for 340B programs.
- Consider participating in CMS’s voluntary Medicare Part D Claims Data 340B Repository to test data submission processes.
TOP STORIES
Hospitals sue to block 340B rebate pilot.
Becker’s Hospital Review · October 9, 2026
- The AHA and others filed a lawsuit against HHS in the U.S. District Court for the District of Maine.
- They argue the revised 340B rebate program could impose over $1 billion in annual costs.
- The lawsuit challenges the shift from upfront discounts to post-sale rebates for certain drugs.
Drugmakers seek to join hospitals’ 340B lawsuit.
Becker’s Hospital Review · October 16, 2026
- AbbVie, Bristol Myers Squibb, and PhRMA filed motions to intervene in the lawsuit.
- They aim to defend HRSA-approved rebate plans for their drugs.
- The motions were filed in the U.S. District Court for the District of Maine.
Bill introduced to delay 340B rebate pilot.
Becker’s Hospital Review · October 13, 2026
- The 340B Rebate Model Delay Act proposes a two-year pause on the rebate pilot.
- It requires upfront discounts from drugmakers during the delay period.
- The bill aims to allow Congress time to consider broader 340B reforms.
FEDERAL POLICY & REGULATORY DEVELOPMENTS
HHS report flags 340B program concerns.
TechTarget · October 12, 2026
- The report raises concerns about the program’s growth and impact on hospital profits.
- It raises issues of spread pricing and hospital consolidation.
- Hospitals argue the program is vital for safety-net providers.
340B PROGRAM DEVELOPMENTS
HRSA approves 340B rebate plans.
MENAFN · October 20, 2026
- HRSA approved rebate plans from 10 drug manufacturers for the revised pilot.
- The pilot takes effect on January 1, 2027.
- Covered entities must submit claims data within 45 days of dispense.
LITIGATION & ENFORCEMENT WATCH
| Court | Matter | Date |
|---|---|---|
| D. Me. | AMERICAN HOSPITAL ASSOCIATION v. KENNEDY — Brief of Amici Curiae by 340B health, america’s essential hospitals, association of american medical colleges, children’s hospital association. Case filed October 9, 2026. [source] | October 20, 2026 |
| M.D. Fla. | Florida Health Sciences Center, Inc. v. Eli Lilly and Company — Response to Motion re motion to Dismiss Plaintiff’s Complaint and As-Applied Challenge to the Constitutionality of Section 501.201 to 501.213, Fla. Stat. Case filed July 2, 2026. [source] | October 14, 2026 |
| S.D.N.Y. | Mount Sinai Hospital v. CVS Health Corporation — Protective ORDER.regarding procedures to be followed that shall govern the handling of confidential material. (.). Case filed May 18, 2026. [source] | October 13, 2026 |
| D.N.H. | Mary Hitchcock Memorial Hospital v. Eli Lilly and Company — Surreply to Reply to 5 motion for Preliminary Injunction Def’s Surreply in Opposition to Plt’s Motion for Preliminary Injunction. Case filed July 27, 2026. [source] | October 6, 2026 |
| 8th Cir. | Astrazeneca Pharmaceuticals, LP v. Marty Jackley — Reply to response to petition for initial hearing en banc. Case filed August 11, 2026. [source] | September 25, 2026 |
| 8th Cir. | Pharm. Res. & Mfr. of America v. Marty Jackley — Motion to file a reply to response,. Case filed August 25, 2026. [source] | September 25, 2026 |
| N.D. Ill. | Novartis Pharmaceuticals Corporation v. Raoul, in his official capacity as Attorney General for the State of Illinois — Order signed by the Honorable Edmond E. Chang. For the reasons stated in the Order, the motion for expedited discovery 34 is denied. Case filed August 7, 2026. [source] | September 24, 2026 |
| E.D. Mo. | AbbVie Inc. v. Hanaway — Memorandum and order: Accordingly, the Court grants Intervenors’ motion to intervene. see order for details. Case filed July 22, 2024. [source] | September 24, 2026 |
MANUFACTURER WATCH
| Manufacturer | Action | Date |
|---|---|---|
| Sanofi | Credit model requiring hospitals to pay WAC and submit claims data before receiving 340B credit. [source] | November 22, 2024 |
SOCIAL MEDIA & STAKEHOLDER SENTIMENT
I conducted a web search for recent stakeholder and social commentary on the U.S. 340B Drug Pricing Program from the past 90 days, focusing on reactions, statements, op-eds, and advocacy positions from hospital and health-center groups, provider and patient advocates, drug manufacturers, PBMs, and policy commentators, including LinkedIn posts, Reddit discussions, and Substack/newsletter opinions.
340B Drug Pricing Program: A Critical Program for Community Health Centers
National Association of Community Health Centers · October 22, 2026
- Main theme: NACHC states the importance of the 340B program for community health centers.
- Stakeholder sentiment: The National Association of Community Health Centers (NACHC) states that the 340B program is essential for community health centers to provide low-cost medications and essential health services to underserved populations.
- Potential implications: The NACHC expresses concern over ongoing actions by drug companies that threaten patient access to critical medicines and essential health services supported by the 340B program.
- Credibility: The National Association of Community Health Centers is a reputable organization representing community health centers across the United States.
WHAT TO WATCH NEXT
- Monitor the outcome of the American Hospital Association v. Kennedy case for potential impacts on the 340B rebate pilot. [source]
- Watch for Congressional action on the 340B Rebate Model Delay Act and its implications for the rebate pilot. [source]
- Track CMS’s decision on the proposed 340B payment cuts and their impact on hospital revenues. [source]
- Stay updated on HRSA’s interim summaries of the 340B rebate pilot findings and evaluations. [source]
End of briefing.
This briefing is provided for informational purposes only and does not constitute legal, regulatory, financial, or compliance advice. Automated summarization may contain errors or omissions, and source materials may change after publication. Recipients should independently verify all information against the cited primary sources before relying on it.
© 2026 MedMatrix Rx. All rights reserved.